**THE STATE OF ISRAEL**

**MINISTRY OF HEALTH**

**TEL AVIV SOURASKY MEDICAL CENTER**

Affiliated to the Tel-Aviv University

Sackler Faculty of Medicine

Municipality of Tel-Aviv-Yafo

6 Weizmann St. Tel-Aviv 64239

Tel: 972-3-6974444

Medical Confidential

This letter contains important medical information, it should be brought to the treating physician as soon as possible in order to ensure continuous treatment

**Nuclear Medicine - PET Exam Findings**

Tel.: 03-6973490/3532 Fax: 03-6973895

Name: **Shachar Yael** **Id. no.: 5392057-5**

 Tel: 052-8444550

Address: Tabenkin Itzhak 24 Tel Aviv-Yafo 6935351

Case: **38966024** Age: **64 Y** Gender: **F**

Referring entity: **Clalit** [HMO]

Ordering Organizational Unit: **Magnetic Resonance – Unit**

**Exams performed**

|  |  |  |
| --- | --- | --- |
| Date performance of exam approved | Time performance of exam approved | Description of Service |
| January 18, 2021 | 09:50 | FDG-PET mapping, glucose tracer, oncological |

**History of Illness**

64-yr. old female, after excision in 2017 of superior segment in the RLL due to neoplastic process. In Nov. 2019, illness returned in the mediastinum, received chemo-radiation therapy.

**Question for investigation**

Follow-up.

**Name of Roentgenologist**

Vera Podokshik

**Description of exam and findings**

Whole-body FDG-PET performed up to mid-thigh.

The exam was performed with the DISCOVERY 690 PET-CT system with simultaneous registration of FDG and CT slices.

Injected dose: 12 mCi

Blood sugar level: 95 mg/dl

Telebrix was given to demonstrate intestinal loops in the CT which was used for registration. Contrast agent was injected IV, CT scan was done in the venous stage.

Comparison with the previous exam of October 2020, which was performed at another hospital.

**Medical confidential Nuclear Medicine – PET findings CONT**

**Name: Shachar Yael Id. no.:5392057-5 Case: 38966024**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Pathological uptake demonstrated (SUV max up to 6) in lymphadenopathy, in the isthmus, in the lymph nodes which grew and demonstrate pathological uptake in the

rt. pulmonary hilum (grew in mass to dimensions of 2\*1.3 cm), in the intracranial node, in two retrocaval nodes. As evidence of progression of the disease.

Weak uptake demonstrated this time as well in rt. paramediastinal post-radiation changes, without change.

Small amount of new rt pleural effusion.

No pathological uptake is seen or new pulmonary nodule in the hilum of the pulmonary parenchyma.

No pathological uptake is demonstrated at additional nodular sites, in the liver, in the spleen, in the adrenals and in the skeleton.

As a reminder, the PET exam with FDG is not efficient in locating metastases in the nervous system and for assessing response to treatment. With this reservation, no pathological uptake of FDG is demonstrated in the brain.

In part of the CT, a hyperdense process in the lt. posterior fossa is once again demonstrated, apparently known meningioma.

**In summary:**

Findings of the exam demonstrate progression in nodular involvement in the isthmus and in the rt. pulmonary hilum – lymph nodes grew slightly and demonstrate pathological uptake.

Stable post-radiation changes in the rt. lung.

Small amount of new rt. pleural effusion.

Outside of the thorax, no neoplastic process with hyper-uptake of FDG was identified in the area of resolution of the PET method.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Name of interpreting physician** | **Medical license no.** | **Specialist diploma no.** | **Date of interpretation** | **Time of interpretation** |
| Dr. Michael Kesler  | 1118288 | 1-36400 | January 18, 2021 | 13:07 |

**Date typed:** Jan. 18, 2021